We are live on
!
Find out more
AC
Armistice Capital Portfolio holdings
AUM
$5.62B
1-Year Est. Return
36.06%
This Fund
S&P 500
This Quarter
Est. Return
-6.51%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$1.59B
AUM Growth
-$241M
(-13%)
Cap. Flow
-$119M
Cap. Flow
% of AUM
-7.49%
Top 10 Holdings %
Top 10 Hldgs %
53.34%
Holding
89
New
20
Increased
22
Reduced
13
Closed
28
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanda Pharmaceuticals
VNDA
|
+$50.3M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$41.3M |
| 3 |
Lowe's Companies
LOW
|
+$36.2M |
| 4 |
United Therapeutics
UTHR
|
+$30.3M |
| 5 |
RH
RH
|
+$23.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pacira BioSciences
PCRX
|
+$40.8M |
| 2 |
CLVS
Clovis Oncology, Inc.
CLVS
|
+$37.9M |
| 3 |
AutoZone
AZO
|
+$28.7M |
| 4 |
Biogen
BIIB
|
+$28.2M |
| 5 |
PLYA
Playa Hotels & Resorts
PLYA
|
+$27.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 31.87% |
| 2 | Consumer Discretionary | 15.3% |
| 3 | Industrials | 5.59% |
| 4 | Consumer Staples | 4.92% |
| 5 | Technology | 1.5% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
AYTU BioPharma
AYTU
$22.4M
| $3.78M | 0.24% |
10,000
| – | – |
|
52
Tapestry
TPR
$30.3B
| $3.17M | 0.2% |
+100,000
| New | +$3.12M |
|
|
VLRX
53
DELISTED
VALERITAS HOLDINGS INC
VLRX
| $2.78M | 0.18% |
1,060,000
+65,000
| +7% | +$313K |
|
54
Larimar Therapeutics
LRMR
$379M
| $2.59M | 0.16% |
181,500
+5,833
| +3% | +$155K |
|
|
BIG
55
DELISTED
Big Lots, Inc.
BIG
| $2.15M | 0.14% |
+75,000
| New | +$2.5M |
|
56
Dave & Buster's
PLAY
$360M
| $2.02M | 0.13% |
+50,000
| New | +$2.54M |
|
|
BLPH
57
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
| $1.71M | 0.11% |
190,667
-2,666
| -1% | -$25.6K |
|
|
MDGSW
58
DELISTED
Medigus Ltd. Series C Warrant
MDGSW
| $1.53M | 0.1% |
1,285,715
| – | – |
|
|
DYNT
59
DELISTED
Dynatronics Corp
DYNT
| $950K | 0.06% |
115,200
| – | – |
|
|
RNTX
60
Rein Therapeutics
RNTX
$65.5M
| $864K | 0.05% |
60,000
-101,692
| -63% | -$2.67M |
|
|
ROX
61
DELISTED
Castle Brands, Inc.
ROX
| $464K | 0.03% |
1,000,000
| – | – |
|
|
62
AutoZone
AZO
$51.4B
| – | – |
-28,000
| Closed | -$28.7M |
|
63
Cenntro
CENN
$8.6M
| – | – |
-2
| Closed | -$460K |
|
64
CALL
Campbell Soup
CPB
$6.75B
| – | – |
-600,000
| Closed | -$22.9M |
|
|
65
Campbell Soup
CPB
$6.75B
| – | – |
-332,000
| Closed | -$12.7M |
|
66
CRISPR Therapeutics
CRSP
$4.68B
| – | – |
-80,000
| Closed | -$2.86M |
|
67
CALL
CVS Health
CVS
$136B
| – | – |
-1,250,000
| Closed | -$74.9M |
|
68
Dick's Sporting Goods
DKS
$18.4B
| – | – |
-400,000
| Closed | -$14.7M |
|
69
Brinker International
EAT
$8.85B
| – | – |
-164,000
| Closed | -$7.28M |
|
70
National Beverage
FIZZ
$3.03B
| – | – |
-496,000
| Closed | -$14.3M |
|
71
Cedar Fair
FUN
$1.88B
| – | – |
-200,000
| Closed | -$10.5M |
|
72
Home Depot
HD
$337B
| – | – |
-112,000
| Closed | -$21.5M |
|
73
Moleculin Biotech
MBRX
$9.61M
| – | – |
-98
| Closed | -$179K |
|
74
Merck
MRK
$320B
| – | – |
-94,320
| Closed | -$7.59M |
|
75
Nike
NKE
$64.1B
| – | – |
-108,000
| Closed | -$9.1M |
|
Similar funds
CRC
RMDI
F
DWM
DCP
EW
O
PA
Armistice Capital's Q2 2019 Portfolio in Review
As of Q2 2019, Armistice Capital held 89 positions worth $1.59B, down 13% from $1.83B the previous quarter. Its ten largest holdings account for 53% of the portfolio.
Armistice Capital withdrew a net $119M in Q2 2019, closing 28 positions and reducing 13 holdings. Its most notable exit was Pacira BioSciences, an estimated $40.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 32% of assets, down from 36% a quarter earlier, followed by Consumer Discretionary and Industrials.
Against the trend, Armistice Capital opened a new position in Vanda Pharmaceuticals worth $44.5M.
- Armistice Capital's largest Q2 2019 buy was Vanda Pharmaceuticals: 3,158,000 shares worth $44.5M.
- Armistice Capital added most to Edgewell Personal Care in Q2 2019, an estimated $20.3M increase.
- Armistice Capital's biggest Q2 2019 reduction was Biogen, cutting an estimated $28.2M.
- Armistice Capital fully exited Pacira BioSciences in Q2 2019, selling an estimated $40.8M.
- Armistice Capital's ten largest holdings make up 53% of its $1.59B portfolio in Q2 2019.
- Armistice Capital opened 20 new positions and closed 28 in Q2 2019.
- Armistice Capital's portfolio value fell 13% quarter-over-quarter to $1.59B.
Based on Armistice Capital's 13F filing for Q2 2019, filed 14 Aug 2019.